{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9416","pValueComment":"Two-sided significance level = 0.05","statisticalComment":"Welch t-test (unequal variances)","statisticalMethod":"t-test, 2 sided"}],"anticipatedPostingDate":"2026-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-12.24","upperLimit":"8.43","value":"-1.90"},{"groupId":"OG001","lowerLimit":"-6.23","upperLimit":"3.24","value":"-1.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"The EORTC QLQ C30 Physical Functioning score measures patient reported limitations in physical activities. Possible scores for each score range from 0 to 100, with higher scores indicating better physical functioning. Change is defined as the time point score minus the baseline score, where positive values indicate improvement for and negative values indicate.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\\^2 IV starts one week prior to RT, then 250 mg/m\\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"RT+ Cetuximab"},{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"RT + Durvalumab"}],"paramType":"MEAN","populationDescription":"Randomized participants with baseline and one-year data.","reportingStatus":"POSTED","timeFrame":"Baseline and one year after end of radiation therapy (approximately 7 weeks)","title":"Change in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30) Physical Functioning Score at One Year","type":"SECONDARY","unitOfMeasure":"score on a scale"}